Unknown

Dataset Information

0

Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition.


ABSTRACT: CYP51 (sterol 14?-demethylase) is an efficient target for clinical and agricultural antifungals and an emerging target for treatment of Chagas disease, the infection that is caused by multiple strains of a protozoan pathogen Trypanosoma cruzi. Here, we analyze CYP51A from the Y strain T. cruzi. In this protein, proline 355, a residue highly conserved across the CYP51 family, is replaced with serine. The purified enzyme retains its catalytic activity, yet has been found less susceptible to inhibition. These biochemical data are consistent with cellular experiments, both in insect and human stages of the pathogen. Comparative structural analysis of CYP51 complexes with VNI and two derivatives suggests that broad-spectrum CYP51 inhibitors are likely to be preferable as antichagasic drug candidates.

SUBMITTER: Cherkesova TS 

PROVIDER: S-EPMC4252588 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3040149 | biostudies-literature
| S-EPMC3714016 | biostudies-literature
| S-EPMC7330235 | biostudies-literature
| S-EPMC5719540 | biostudies-literature
| S-EPMC7193919 | biostudies-literature
| S-EPMC4148231 | biostudies-literature
| S-EPMC1559615 | biostudies-literature
2023-04-11 | GSE229354 | GEO
| S-EPMC2223453 | biostudies-literature
| S-EPMC108675 | biostudies-literature